Selank
Also known as: Selank Acetate, TP-7
Selank is a synthetic peptide analog of the endogenous tetrapeptide tuftsin. It was developed in Russia for its anxiolytic and nootropic properties and has been studied for effects on stress response and cognitive function.
Selank Overview & Molecular Profile
Selank is a heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the naturally occurring tetrapeptide tuftsin with additional amino acids for enhanced stability. It has been approved in Russia as an anxiolytic medication. Research focuses on its effects on anxiety, cognitive function, and immune modulation. Unlike benzodiazepines, Selank does not cause sedation, dependence, or withdrawal symptoms in research settings.
Mechanism of Action: Neuroprotection & Synaptic Plasticity
Selank modulates the expression of brain-derived neurotrophic factor (BDNF) and affects the balance of various neurotransmitter systems including GABA, serotonin, and dopamine. It inhibits enkephalin-degrading enzymes, leading to increased enkephalin levels. Research indicates effects on gene expression related to immune function and stress response. The peptide also shows immunomodulatory effects through its relationship to tuftsin.
Research-Observed Effects
Anxiolytic Activity
Extensive clinical and preclinical research demonstrates Selank's potent anxiety-reducing effects through modulation of GABAergic neurotransmission and serotonin system regulation without causing sedation or cognitive impairment commonly associated with benzodiazepine anxiolytics. Studies in animal models of generalized anxiety disorder show significant reduction in anxiety-related behaviors within 30 minutes of intranasal administration, with effects persisting for several hours beyond the peptide's plasma half-life. Unlike traditional anti-anxiety medications, Selank does not produce tolerance, dependence, or withdrawal symptoms even after prolonged administration in research settings, making it valuable for chronic anxiety treatment studies. The peptide inhibits enkephalin-degrading enzymes including enkephalinase and carboxypeptidase, leading to increased endogenous enkephalin levels that contribute to its calming effects through opioid receptor modulation. Research indicates potential applications in social anxiety disorder treatment, panic disorder mechanisms, and stress-related anxiety research where sedation-free anxiolysis is essential for accurate behavioral assessment.
Cognitive Enhancement
Research demonstrates significant improvements in memory consolidation, learning acquisition, and sustained attention through Selank's modulation of brain-derived neurotrophic factor (BDNF) expression in hippocampal and cortical brain regions essential for cognitive function. Studies show the peptide enhances long-term potentiation (LTP), the cellular mechanism underlying memory formation, with improvements of 25-40% in memory retention tests compared to control groups in animal models. Selank influences the expression of over 80 genes related to cognitive function including those involved in neurotransmitter synthesis, synaptic plasticity, and neuronal survival pathways. Research in attention and focus paradigms demonstrates enhanced performance on sustained attention tasks and reduced cognitive interference, suggesting potential applications in attention deficit research and cognitive aging studies. The peptide's nootropic effects appear synergistic with its anxiolytic properties, as reduced anxiety contributes to improved cognitive performance in research subjects, making it valuable for studying the anxiety-cognition relationship.
Immunomodulation
As a synthetic analog of the endogenous immunomodulatory peptide tuftsin, Selank demonstrates significant effects on immune cell function including enhanced phagocytic activity of monocytes and macrophages, increased natural killer cell cytotoxicity, and modulation of cytokine production profiles. Research shows the peptide stimulates IL-6 expression while balancing pro-inflammatory and anti-inflammatory cytokine ratios, contributing to optimized immune response without excessive inflammation. Studies document improved antibody production and enhanced T-lymphocyte function in immunocompromised research models, suggesting potential applications in immunodeficiency research and adjuvant therapy studies. The immunomodulatory effects appear independent of the peptide's anxiolytic actions, operating through specific tuftsin receptor-mediated pathways on immune cells. Research has explored Selank's potential in autoimmune condition models, viral infection research, and immune system optimization studies, with findings indicating it may help restore balanced immune function in dysregulated states.
Stress Adaptation
Research demonstrates Selank's significant adaptogenic properties through modulation of the hypothalamic-pituitary-adrenal (HPA) axis, the primary stress response system, resulting in normalized cortisol levels and improved stress resilience in chronic stress models. Studies show the peptide reduces stress-induced increases in corticosterone (the rodent equivalent of cortisol) by up to 50% while simultaneously enhancing expression of stress-protective heat shock proteins and antioxidant enzymes. Selank appears to enhance serotonin metabolism and dopamine turnover in brain regions associated with stress processing, contributing to improved emotional regulation under challenging conditions. Research in models of chronic unpredictable stress demonstrates preserved cognitive function and reduced depressive-like behaviors in Selank-treated subjects compared to untreated controls. The peptide's stress-protective effects have implications for research into post-traumatic stress disorder (PTSD), burnout syndrome, and chronic fatigue conditions where dysregulated stress responses contribute to pathology.
Research Dosing Information
Russian clinical use involves intranasal administration at 250-500 mcg, 2-3 times daily. Research protocols vary based on study objectives and model organisms used.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo
Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA (2008). Doklady Biological Sciences
This foundational study examined Selank's effects on neurotrophin expression in the rat hippocampus using intranasal administration and quantitative PCR analysis of gene expression changes. Researchers demonstrated significant upregulation of brain-derived neurotrophic factor (BDNF) mRNA expression, with increases of approximately 30-45% observed within 24 hours of treatment. The study also documented enhanced expression of nerve growth factor (NGF) and neurotrophin-3 (NT-3), suggesting broad neurotrophic activity. These findings provided crucial mechanistic insight into Selank's cognitive enhancement properties, establishing the neurotrophin hypothesis as a key explanation for its nootropic effects. The research has significant implications for understanding peptide-based approaches to cognitive enhancement and neuroprotection in conditions characterized by reduced neurotrophic support.
Anxiolytic effects of Selank in elevated plus-maze and behavior despair tests
Seredenin SB, Kozlovskaya MM, et al. (2001). Eksperimental'naia i Klinicheskaia Farmakologiia
This comprehensive behavioral pharmacology study evaluated Selank's anxiolytic properties using multiple validated anxiety models including the elevated plus-maze, open field test, and forced swimming test in rats. Researchers administered Selank intranasally at doses ranging from 100 to 500 mcg/kg and observed significant dose-dependent reductions in anxiety-related behaviors, with optimal effects at 300 mcg/kg. Importantly, the study demonstrated that Selank produced anxiolytic effects comparable to diazepam without the sedative, muscle-relaxant, or memory-impairing side effects characteristic of benzodiazepine drugs. The absence of motor coordination impairment was confirmed through rotarod testing, establishing Selank's favorable side effect profile. These findings contributed to Selank's approval as an anxiolytic medication in Russia and provided foundational evidence for its clinical development.
Effect of Selank on cognitive processes after hypoxia stress
Kozlovskaia MM, et al. (2006). Bulletin of Experimental Biology and Medicine
This study investigated Selank's neuroprotective and cognitive-preserving effects in a hypoxia-induced cognitive impairment model, examining the peptide's ability to prevent or reverse memory deficits following oxygen deprivation. Rats were subjected to acute hypobaric hypoxia and tested in passive avoidance and Morris water maze paradigms to assess learning and memory function. Selank administration significantly protected against hypoxia-induced cognitive impairments, with treated animals showing 60-75% preservation of learning capacity compared to untreated hypoxic controls. The study revealed that Selank's protective effects were associated with reduced oxidative stress markers and maintained neuronal integrity in hippocampal regions critical for memory. These findings suggest potential applications in stroke research, high-altitude medicine, and conditions involving cerebral hypoxia.
Comparative Research
Explore in-depth research analyses and comparative studies featuring Selank.
Frequently Asked Questions
Semax
C37H51N9O10S
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research.
Dihexa
C27H44N4O5
Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.